

Factsheet FY/2016



COMPANY PROFILE

Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide services for hospitals and other health care facilities. More than 230,000 employees have dedicated themselves to the service of health in over 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions	FY/2016	Change	FY/2015	Change
Sales and Earnings				
Sales	29,083	5%	27,626	19%
EBIT ¹	4,327	9%	3,958	25%
Net income ^{1,2}	1,593	12%	1,423	31%
Earnings per ord. share in € ^{1,2}	2.92	12%	2.61	30%
Balance sheet and cash flow				
Total assets	46,447	8%	42,959	8%
Non-current assets	34,648	7%	32,480	9%
Equity ³	20,420	13%	18,003	16%
Equity ratio ³	44%	--	42%	--
Net debt/EBITDA ^{4,5}	2.34	--	2.68	--
Investments ⁶	2,547	26%	2,029	-47%
Operating cash flow	3,574	7%	3,327	29%
Operating cash flow in % of sales	12.3%	--	12.0%	--
Profitability				
EBIT margin ¹	14.9%	--	14.3%	--
Return on equity after taxes (ROE) ^{1,2}	12.7%	--	13.0%	--
Return on operating assets (ROOA) ⁴	10.1%	--	10.1%	--
Return on invested capital (ROIC) ⁴	8.5%	--	8.3%	--
Employees (December, 31)	232,873	5%	222,305	3%

¹ 2015 before special items

² Net income attributable to shareholders of Fresenius SE & Co. KGaA

³ Including noncontrolling interest


⁴ 2016 pro forma acquisitions; 2015 before special items

⁵ At LTM average exchange rates for both net debt and EBITDA

⁶ Investments in property, plant and equipment, and intangible assets, acquisitions

GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.



¹ As of December 31, 2016


BUSINESS SEGMENTS

€ in millions		FY/2016	Change	FY/2015	Change
	Sales	16,181	7%	15,086	27%
	EBIT	2,383	14%	2,097	24%
	Sales	6,007	1%	5,950	16%
	EBIT ¹	1,224	3%	1,189	36%
	Sales	5,843	5%	5,578	6%
	EBIT ¹	682	7%	640	16%
	Sales	1,160	4%	1,118	7%
	EBIT	69	8%	64	8%


¹ 2015 before special items

- **Fresenius Medical Care** is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure. As of December 31, 2016, Fresenius Medical Care was treating 308,471 patients in 3,624 dialysis clinics.
- **Fresenius Kabi** Fresenius Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products.
- **Fresenius Helios** is Europe's largest private hospital operator. In Germany, HELIOS operates 112 hospitals, thereof 88 acute care clinics (including seven maximum care hospitals in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin, Wiesbaden and Wuppertal) and 24 post-acute care clinics. Through Quirónsalud, Fresenius Helios operates 43 hospitals, 39 outpatient centers and around 300 Occupational Risk Prevention (ORP) centers in Spain.
- **Fresenius Vamed** manages projects and provides services for hospitals and other health care facilities worldwide. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management, to total operational management.

SALES BY REGION




SALES BY BUSINESS SEGMENT




FRESENIUS SHARE / ADR

	Share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of shares (Dezember 31, 2016)	547,208,371
Market capitalization (Dezember 31, 2016)	€40.6 billion

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX



DEVELOPMENT SHARE DIVIDENDS IN €



¹ Proposal

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick


General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Stephan Sturm (Chairman), Mats Henriksson, Dr. Francesco De Meo, Dr. Jürgen Götz, Rice Powell, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick

SHARE PERFORMANCE¹

4rd quarter	+4,6%
1 year	+12,6%
3 years	+99,6%
5 years	+211,7%
10 years	+340,5%

¹ Effective date/closing price: December 31, 2016

FRESENIUS GROUP: FINANCING MIX



GROUP OUTLOOK 2017

	Targets 2017 ¹
Sales, growth (in constant currency)	15% – 17%
Net income ² , growth (in constant currency)	17% – 20%
Capital expenditure	~6% of group sales

¹ According to IFRS

² Net income attributable to shareholders of Fresenius SE & Co. KGaA

For the outlook of the business segments please see the Investor News of February 22, 2017.

FINANCIAL CALENDAR

	Dates
Report on 1st quarter 2017	May 3, 2017
Annual General Meeting, Frankfurt/Main	May 12, 2017
Report on 2nd quarter 2017	August 1, 2017
Report on 3rd quarter 2017	November 2, 2017

Please note that these dates could be subject to modifications.

CONTACT

Fresenius SE & Co. KGaA

Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H.
e-mail: ir-fre@fresenius.com
Internet: www.fresenius.com

Markus Georgi

Senior Vice President Telephone: ++49 61 72 6 08-24 85
Investor Relations Telefax: ++49 61 72 6 08-24 88

Follow us on twitter and linkedin

[Follow @fresenius_ir](https://twitter.com/fresenius_ir)

[LinkedIn](#)